pharmaphorum January 13, 2022
Phil Taylor

In 2020, over half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders, overtaking the amount going to drug manufacturers for the first time, according to a new study.

The report from Berkeley Research Group (BRG) – which was funded by the pharma industry trade group PhRMA – reveals a steady decrease in the proportion received by drugmakers from around 67% in 2013 to 49.5% in 2020.

Over the same period, total gross expenditures on brand and generic medicines nearly doubled – from $268 billion to $517 billion, according to the report.

The data plays into the ongoing debate about the factors behind high medicine prices in the US, with pharma manufacturers and the...

Today's Sponsors

Patient Bond
Institute for Healthcare Improvement

Today's Sponsors

Oliver Wyman
Patient Bond

Today's Sponsor

Patient Bond

Topics: Biotechnology, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Pricing / Spending, Provider, Supply Chain, Survey / Study, Technology, Trends
Mass General dinged for spending growth by state regulator
The Forest for the Trees: National Health Expenditures and Healthcare Reform
Billionaire Mark Cuban steps up assault on US medicine prices
Book Review: The Right Price
Health cost regulator reprimands dominant Mass. hospital system